Akebia Therapeutics Inc (AKBA)

1.34 +0.01 (+0.75%) USD  |  NASDAQ  |  Apr 26, 16:00
1.335 0.00 (0.00%) Pre-Market: 20:00
More

Akebia Therapeutics Research and Development Expense (Quarterly): 9.865M for Dec. 31, 2023

Research and Development Expense (Quarterly) Chart

Historical Research and Development Expense (Quarterly) Data

View and export this data back to 2013. Upgrade now.
Date Value
December 31, 2023 9.865M
September 30, 2023 13.33M
June 30, 2023 20.20M
March 31, 2023 19.69M
December 31, 2022 32.10M
September 30, 2022 28.03M
June 30, 2022 26.03M
March 31, 2022 43.83M
December 31, 2021 29.56M
September 30, 2021 40.47M
June 30, 2021 37.21M
March 31, 2021 40.61M
December 31, 2020 37.58M
September 30, 2020 46.86M
June 30, 2020 52.82M
March 31, 2020 81.23M
December 31, 2019 80.41M
September 30, 2019 74.51M
June 30, 2019 85.69M
March 31, 2019 82.35M
December 31, 2018 87.05M
September 30, 2018 70.63M
Date Value
June 30, 2018 71.92M
March 31, 2018 61.40M
December 31, 2017 68.38M
September 30, 2017 58.71M
June 30, 2017 43.75M
March 31, 2017 60.05M
December 31, 2016 33.44M
September 30, 2016 31.24M
June 30, 2016 30.88M
March 31, 2016 20.24M
December 31, 2015 14.24M
September 30, 2015 15.60M
June 30, 2015 6.505M
March 31, 2015 6.664M
December 31, 2014 4.933M
September 30, 2014 6.648M
June 30, 2014 5.525M
March 31, 2014 6.158M
December 31, 2013 1.311M
September 30, 2013 3.24M
June 30, 2013 2.453M
March 31, 2013 1.898M

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Quarterly) Range, Past 5 Years

9.865M
Minimum
Dec 2023
85.69M
Maximum
Jun 2019
42.11M
Average
37.58M
Median
Dec 2020

Research and Development Expense (Quarterly) Benchmarks

Ocugen Inc 9.504M
Aquestive Therapeutics Inc 2.888M
SELLAS Life Sciences Group Inc 5.097M
Protagonist Therapeutics Inc 28.90M
Stoke Therapeutics Inc 21.78M